Educational use only. Check doses against the product monograph and local protocols.

diuretics

in review 5 min read Updated 2026-10-21
diuretics

Each class blocks Na⁺ reabsorption at one nephron segment; potency follows how much Na⁺ that segment handles and how much the downstream segments can reclaim. Loops are the most potent and the decongestion backbone; thiazides, acetazolamide and amiloride are add-ons, blood pressure drugs, or electrolyte tools. Choosing and escalating diuretics in acute HF → diuretic therapy in acute heart failure. MRAs → mineralocorticoid receptor antagonists; vaptans → tolvaptan; SGLT2i → SGLT2 inhibitors.


by segment

classsite / transporterFENa potencyurineacid–baseK⁺Ca²⁺
acetazolamideproximal tubule — carbonic anhydrase~4%NaHCO₃-richmetabolic acidosis↓—
loopthick ascending limb — NKCC220–25%dilute (hypotonic)contraction alkalosis↓↓ (calciuric)
thiazidedistal convoluted tubule — NCC5–8%concentratedalkalosis↓↓↑ (retains)
amiloridecollecting duct — ENaC~2%—mild acidosis↑—
  • loops, thiazides and acetazolamide are protein-bound and reach the lumen by proximal tubular secretion → low renal blood flow, hypoalbuminaemia and CKD blunt them; amiloride too
  • loops and thiazides waste Cl⁻ → hypochloraemic alkalosis → renin ↑ → diuretic resistance; acetazolamide spares Cl⁻
  • loops cause hypernatraemia (lose free water); thiazides cause hyponatraemia (block the diluting segment)

loop diuretics

furosemidebumetanidetorsemideethacrynic acid
oral equivalent40 mg0.5–1 mg10–20 mg—
oral bioavailability10–100% (erratic; gut oedema)80–100%80–100%—
IV vs oraldouble IV dose for oral (CCS: ~50% bioavailability)IV ≈ oralIV ≈ oral—
half-life1.5–3 h1–1.5 h3–6 h—
max IV daily dose400–600 mg (up to 1000 mg in severe CKD)10–15 mg200–300 mg—
sulfonamideyesyesyesno
  • threshold drug: nothing below the natriuretic threshold (rises as GFR falls); above the ceiling, a bigger dose only prolongs the effect → dose for threshold, frequency for duration (usually 2–3×/day, ≥6 h apart, to avoid rebound Na⁺ retention; once daily if response is good)
  • dosing in ADHF (naive ≥20–40 mg IV; chronic 1–2.5× home dose IV; DOSE-AHF) → diuretic therapy in acute heart failure
  • erratic furosemide absorption → switch to bumetanide or torsemide; TRANSFORM-HF (2023): torsemide vs furosemide → same 12-month mortality
  • no survival benefit from loops — symptom drugs
  • other uses: hyperkalaemia (with intact renal function), hypercalcaemia after volume repletion, oedema of nephrotic syndrome and cirrhosis (with spironolactone)
  • sulfonamide antibiotic allergy is not a contraindication (no N4-arylamine); ethacrynic acid only for documented allergy to the loop itself — more ototoxic

thiazide and thiazide-like diuretics

agenthalf-lifeoral doserole
chlortalidone45–60 h12.5–25 mg (HTN); up to 100 mghypertension; works in stage 4 CKD (CLICK (2021)); same CV outcomes as HCTZ with more hypokalaemia (6.0% vs 4.4%)
indapamide14–24 h1.25–2.5 mghypertension; less metabolic effect
hydrochlorothiazide6–15 h12.5–25 mg (HTN); 25–100 mg as diuretic add-oncommon in combinations; weakest per mg
metolazone6–20 h2.5–10 mg (max 20)add-on to loops in diuretic resistance; slow absorption — give hours before the loop
chlorothiazideshort500–1000 mg IVIV add-on when NPO; give just before the loop
  • uses: hypertension — HTN Canada 2025 no longer prefers thiazide-like over thiazide; usually as a single-pill combination with ACEi/ARB; breaking distal-nephron resistance in HF (CLOROTIC (2023): more weight loss, more Cr rise and electrolyte disturbance, no outcome change); hypercalciuric stones; nephrogenic DI (paradoxical ↓ urine volume)
  • effective at eGFR <30 — the “useless below 30” teaching is outdated for chlortalidone and metolazone
  • chronic outpatient loop + thiazide → severe electrolyte disturbance that goes unnoticed → avoid without close lab follow-up
  • AEs: hyponatraemia (stop if Na⁺ <125), hypokalaemia (2–3 K⁺ lost per Na⁺; worse with high aldosterone), hypercalcaemia, hyperuricaemia/gout, hyperglycaemia, hypomagnesaemia

acetazolamide

  • inhibits proximal carbonic anhydrase → NaHCO₃ diuresis; spares Cl⁻ → more Cl⁻ reaches the macula densa → renin suppressed; corrects contraction alkalosis
  • ADHF: 500 mg IV daily added to loop — ADVOR (2022): decongestion by day 3 42% vs 31%, stay 1 day shorter, no change in death or readmission; best with alkalosis or hypochloraemia → diuretic therapy in acute heart failure
  • self-limiting: the acidosis it causes reduces filtered HCO₃⁻ → effect wanes over 2–3 days
  • other uses: metabolic alkalosis (e.g. post-hypercapnic, diuretic-induced), acute mountain sickness, idiopathic intracranial hypertension, glaucoma
  • max 500 mg TID; HF data are for IV — no outcome data for oral in ADHF
  • avoid: hypercapnic or respiratory acidosis without ventilation (removes metabolic compensation), severe hepatic disease (encephalopathy), severe hypokalaemia
  • AEs: metabolic acidosis, paraesthesias, hypokalaemia, AKI, sulfonamide-type rash; stones with chronic use

amiloride

  • blocks ENaC directly (not via the aldosterone receptor) → onset ~2 h vs 48–72 h for spironolactone; weak natriuretic alone
  • counteracts loop/thiazide side effects: ↓ K⁺ secretion, ↓ H⁺ secretion (alkalosis), ↓ Mg²⁺ wasting
  • 5–10 mg PO daily (max 20); accumulates when GFR <50 (half-life up to 144 h) → start low, check K⁺
  • specific uses: Liddle syndrome (ENaC gain of function); lithium-induced nephrogenic DI (blocks lithium entry via ENaC)
  • avoid if K⁺ >5.0; hyperkalaemia additive with ACEi/ARB/MRA
  • choose amiloride over triamterene (triamterene: stones, interstitial nephritis, AKI)

ototoxicity and electrolytes (all classes)

  • ototoxicity (loops): tinnitus, reversible or permanent hearing loss → risk with rapid injection, severe renal impairment, above-recommended doses, hypoproteinaemia, aminoglycosides, ethacrynic acid → infuse high-dose IV furosemide ≤4 mg/min
  • replace K⁺ as KCl (Cl⁻ is part of the fix); replace Mg²⁺ or K⁺ won’t correct
  • K⁺-sparing partner (spironolactone 25 mg or amiloride) limits K⁺ and Mg²⁺ loss in combination regimens

Prepared 2026-10-21. Not yet verified — check every number against the sources.

Key references

+6 more sources

Suggest a correction diuretics